Expanding the Targets Available to Therapeutic Antibodies via Novel Disease-specific Markers

REFERENCES

• Wittman VP, Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177(6):4187–4195.
   Google Scholar
• Weidanz JA, Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 2006;177(8):5088–5097.
   Google Scholar
• Weidanz JA, Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods. 2007;318(1–2):47–58.
   Google Scholar
• Cohen CJ, Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002;62(20):5835–5844.
   Google Scholar
• Denkberg G, Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A. 2002;99(14):9421–9426.
   Google Scholar
• Andersen PS, A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A. 1996;93(5):1820–1824.
   PubMed Web of Science ®Google Scholar
• Porgador A, Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6(6):715–726.
   PubMed Web of Science ®Google Scholar
• Nishida M, Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol. 2007;31(1):29–40.
   Google Scholar
• Vega MI, Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res. 2009;15(21):6582–6594.
   PubMed Web of Science ®Google Scholar
• Carballido E, Fishman M. Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep. 2011;13(2):112–119.
   Google Scholar
• Celis E, Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 1994;31(18):1423–1430.
   Google Scholar
• Wolfel T, Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer. 1993;55(2):237–244.
   Google Scholar
• Kawakami Y, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347–352.
   PubMed Web of Science ®Google Scholar
• Dudley ME, A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25(3):243–251.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14639–14645.
   PubMed Web of Science ®Google Scholar
• Hughes MS, Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16(4):457–472.
   PubMed Web of Science ®Google Scholar
• Verma B, TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol. 2011;186(5):3265–3276.
   PubMed Web of Science ®Google Scholar
• Hawkins OE, Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res. 2008;7(4):1445–1457.
   PubMed Web of Science ®Google Scholar
• Verma B, Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunol Immunother. CII, 2010;59(4):563–573.
   Google Scholar
• Verma B, TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184(4):2156–2165.
   Google Scholar
• Kim S, Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 2010;184(8):4423–4430.
   Google Scholar
• Hawkins O, An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011;186(11):6607–6616.
   PubMed Web of Science ®Google Scholar
• Hunt DF, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science. 1992;255(5049):1261–1263.
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody. J Cellular Physiol. 2010;225(3):664–672.
   Google Scholar